CBIO insider buying and SEC filings, explained
Crescent Biopharma, Inc. · CIK 1253689
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- E9
- Fiscal year end
- Dec 31
- Former names
- GLYCOMIMETICS INC
Insider activity in the last 12 months
Bought
$30.6M
Insiders who bought
1
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$1.5M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 16, 2026 | Planned (10b5-1) | Ryan Lynch (Chief Accounting Officer) sold 240 shares at about $17.90 ($4K), marked as a 10b5-1 plan trade. Holdings down 2% to 13,631 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 16, 2026 | Planned (10b5-1) | Jan Pinkas (Chief Scientific Officer) sold 658 shares at about $17.90 ($12K), marked as a 10b5-1 plan trade. Holdings down 3% to 21,581 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 16, 2026 | Planned (10b5-1) | Ellie Eunkyung Im (Chief Medical Officer) sold 623 shares at about $17.90 ($11K), marked as a 10b5-1 plan trade. Holdings down 3% to 21,446 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 16, 2026 | Planned (10b5-1) | Richard William Scalzo (CFO) sold 568 shares at about $17.90 ($10K), marked as a 10b5-1 plan trade. Holdings down 3% to 19,730 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 16, 2026 | Planned (10b5-1) | Barbara Harlin Bispham (Officer) sold 620 shares at about $17.90 ($11K), marked as a 10b5-1 plan trade. Holdings down 3% to 18,710 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 16–18, 2026 | Planned (10b5-1) | Joshua T Brumm (CEO and Director) sold 9,447 shares between Sep 16 and Sep 18 at about $16.91 ($160K), marked as a 10b5-1 plan trade. Holdings down 3% to 271,765 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 16–18, 2026 | Planned (10b5-1) | Jonathan McNeill (President / COO) sold 4,570 shares between Sep 16 and Sep 18 at about $16.90 ($77K), marked as a 10b5-1 plan trade. Holdings down 3% to 134,588 shares. | SEC filing Filed Sep 18, 2026 |
| Jul 16, 2026 | Other purchase | Peter Evan Harwin (Director and 10% owner) bought 525,897 Pre-Funded Warrant (Right to Buy) indirectly (by entity) at $14.50 ($7.6M), reported as a purchase (code P). Holdings by entity up 30% to 2,294,037 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed Jul 20, 2026 |
| Jul 16, 2026 | Purchase (code P) | Peter Evan Harwin (Director and 10% owner) bought 853,450 shares indirectly (by entity) at $14.50 ($12.4M), reported as a purchase (code P). Holdings by entity up 31% to 3,601,316 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed Jul 20, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Ryan Lynch (Chief Accounting Officer) sold 465 shares at about $17.99 ($8K), marked as a 10b5-1 plan trade. Holdings down 3% to 13,871 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Jan Pinkas (Chief Scientific Officer) sold 1,288 shares at about $17.99 ($23K), marked as a 10b5-1 plan trade. Holdings down 5% to 22,239 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Richard William Scalzo (CFO) sold 1,112 shares at about $17.99 ($20K), marked as a 10b5-1 plan trade. Holdings down 5% to 20,298 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Barbara Harlin Bispham (Officer) sold 1,218 shares at about $17.99 ($22K), marked as a 10b5-1 plan trade. Holdings down 6% to 19,330 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Ellie Eunkyung Im (Chief Medical Officer) sold 1,219 shares at about $17.99 ($22K), marked as a 10b5-1 plan trade. Holdings down 5% to 22,069 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Jonathan McNeill (President / COO) sold 20,549 shares at about $17.99 ($370K), marked as a 10b5-1 plan trade. Holdings down 13% to 139,158 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Joshua T Brumm (CEO and Director) sold 42,305 shares at about $17.99 ($761K), marked as a 10b5-1 plan trade. Holdings down 13% to 281,212 shares. | SEC filing Filed Jun 23, 2026 |
| Dec 4, 2025 | Other purchase | Peter Evan Harwin (Director and 10% owner) bought 131,434 Pre-Funded Warrant (Right to Buy) indirectly (by entity) at $13.41 ($1.8M), reported as a purchase (code P). Holdings by entity up 8% to 1,768,140 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed Dec 8, 2025 |
| Dec 4, 2025 | Purchase (code P) | Peter Evan Harwin (Director and 10% owner) bought 1,360,000 shares indirectly (by entity) at $13.41 ($18.2M), reported as a purchase (code P). Holdings by entity up 98% to 2,747,866 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed Dec 8, 2025 |
15 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow CBIO in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.